4/29/2016 | PP | Durect greenshoe exercise increases public offering to $17.25 million
|
4/26/2016 | PP | Durect prices $15 million public offering of common stock at $1.25
|
4/25/2016 | PP | Durect plans to conduct public offering of its common stock
|
11/13/2013 | PP | Durect greenshoe exercised for $11.5 million public offering of stock
|
11/8/2013 | PP | Durect prices $10 million public offering of its common stock at $1.40
|
11/7/2013 | PP | Durect announces plans to price a public offering of its common stock
|
12/6/2012 | PP | Durect prices $12.6 million public offering of common stock at $0.90
|
5/4/2012 | CVPF | Durect files $50 million shelf covering stock, preferreds and debt
|
7/1/2010 | PP | New Issue: Durect seals $50 million two-year committed equity financing facility
|
9/11/2009 | PP | New Issue: Durect orchestrates $10 million registered direct offering of stock
|
9/11/2009 | PP | Market Commentary: Durect to raise funding for development; DARA aims for $2.5 million; Urodynamix to place stock
|
11/4/2008 | CVHY | Durect files $75 million shelf registration
|
6/17/2008 | CV | Durect 6.25% convertibles exchanged for 7.5 million shares at maturity
|
10/23/2007 | CV | Durect holder agrees to convert $l.75 million of 6.25% convertibles
|
10/11/2007 | CV | Durect holders agree to convert $5 million of 6.25% convertibles
|
10/5/2007 | CV | Durect holder agrees to convert $2.8 million of 6.25% convertibles
|
9/27/2007 | CV | Durect holder agrees to convert $2 million of 6.25% convertibles
|
9/17/2007 | CV | Durect issues shares, cash for $2.2 million of 6.25% convertibles
|
11/3/2006 | BT | Durect's cash dips by $3.4 million during Q3, product revenue rises
|
8/2/2006 | BT | Pain Therapeutics, King start phase 1 trial for Oradur-based pain reliever
|
7/11/2006 | BT | Durect says it will announce new developmental product by end of 2006
|
5/31/2006 | BT | Market Commentary: Gentium gains on PIPE; Cubist holders await convertible smoke to clear; Crucell up; Durect higher
|
5/31/2006 | BTCV | Durect issues 6.35 million shares, cash for $20 million 6.25% convertibles
|
5/5/2006 | BT | Durect begins pivotal phase 3 program for pain medicine Remoxy
|
4/27/2006 | BT | Durect: Phase 2 study of Saber-Bupivacaine in hernia patients meets primary endpoints
|
2/17/2006 | BT | Durect: Pain drug Remoxy gets Special Protocol Assessment, begins phase 3 trial
|
2/8/2006 | BT | Durect's 2006 milestones include advancing pain depot through phase 2, 3 programs
|
1/26/2006 | BT | Market Commentary: Altus rockets out of gate; Teva talk tightened; Alexion zooms; Amylin better; Cephalon gains; Nektar rises
|
1/26/2006 | BT | Durect to conduct more phase 2 studies of pain-relief depot Saber-Bupivacaine
|
1/25/2006 | BT | Durect, Endo extend Chronogesic pact
|
12/30/2005 | BT | Durect says study shows Transdur-Sufentanil patch performed as designed
|
11/30/2005 | BT | Market Commentary: Adams secondary launched; Isis off; Durect up; Inspire, BioCryst rocket up; Merck bonds weaker
|
11/17/2005 | BT | Market Commentary: Gilead off on reports of deaths; Onyx deal at bat; Durect rises on upgrade, but some buyers hesitate
|
11/15/2005 | BT | Durect greenshoe exercised, raising follow-on, secondary offering to $42.55 million
|
11/10/2005 | BT | Market Commentary: King Pharma off, Pain increases; ViroPharma falls on generic risk; Eyetech, OSI seesaw on merger
|
11/2/2005 | BT | New Issue: Durect prices $37 million follow-on, secondary offering at $5 per share
|
11/2/2005 | BT | Market Commentary: Novavax stock slips 12.3% on $18 million direct placement; convertible biotech names mixed
|
10/31/2005 | BT | Market Commentary: NeoPharma skyrockets on new CEO; Charles River Labs higher; Nabi, Indevus, Invitrogen up
|
10/28/2005 | BT | Market Commentary: Accentia drops on IPO debut; Point Therapeutics up on deal delay; Myriad Genetics falls
|
10/27/2005 | BT | Durect plans follow-on sale of 7.4 million shares via Morgan Stanley next week
|
10/27/2005 | BT | Market Commentary: NxStage soars on IPO debut; Durect launches equity deal; Cell Therapeutics deal abuzz; Amylin plunges
|
10/18/2005 | BT | Durect: Positive results for phase II Saber-Bupivacaine trial
|
10/14/2005 | BT | Market Commentary: Predix, Electro-Optical IPOs imminent; Durect gains on trial news; Voyager IPO talk seen aggressive
|
10/14/2005 | CV | Market Commentary: Energy names bounce; Duke trades; autos remain a focus; Jakks Pacific adds
|
10/14/2005 | BT | Durect begins phase III studies on Alzheimer's treatment
|
10/14/2005 | BT | Durect rated overweight by Global Crown
|
10/13/2005 | BT | Durect files $75 million stock shelf
|
10/13/2005 | BT | Market Commentary: Human Genome finds volatility players get it; Access Pharma off, then steadies; Endo, Noven firm
|
9/9/2005 | BT | Market Commentary: Genomic talk surfaces; Voyager files IPO; Elan joins Biogen fall on restructuring; Sepracor lifted
|
9/6/2005 | BT | Market Commentary: Chiron rises on rejection of bid from Novartis; Barr, Teva gain; New River higher; Andrx falls
|
7/22/2005 | BTCV | Durect exchanges $5 million 6.25% convertibles for stock
|
7/22/2005 | BT | Market Commentary: Momenta gains at open, then goes south; Adams up against market; Durect convertibles up on buyback
|
7/14/2005 | BT | Market Commentary: Genentech active; CryoCor IPO trades up, sinks; Mylan prices tight, center; BioMarin off on follow-on
|
7/14/2005 | CV | Market Commentary: GM, Ford convertibles move up in active trade; AMD, Genzyme, airlines also gain, other sectors quiet
|
7/5/2005 | BT | Market Commentary: Voyager plans IPO; Able Labs plunges; Mylan Labs launch seen; Boston Scientific up, J&J lower
|
6/29/2005 | BT | Market Commentary: CV Therapeutics, Lonza upsize convertibles, both higher in trade; Millennium gains on new CEO
|
6/28/2005 | BT | Durect initiated by Oppenheimer at buy
|
6/13/2005 | CV | Market Commentary: Invitrogen launches $300 million convertible; Connetics, Cephalon stir market; Northwest hits turbulence
|
3/2/2005 | CV | Market Commentary: Chiron boosted by lifting of U.K. flu vaccine ban; Charter slips further; Maurel & Prom trades up
|
11/2/2004 | CV | Market Commentary: Deal flow seen improving after election; Durect eyed; Delta 8s ease; Ivax off again
|
8/31/2004 | CV | Market Commentary: Six Flags higher on Gates, Redskins owner play; IMC Global rises; Albertson's off
|
3/25/2004 | CV | Market Commentary: Chesapeake Energy lags other new paper at par; Grey Wolf talked at reoffer price of 99
|
7/11/2003 | CV | Durect says greenshoe exercised, raising convertibles to $60 million
|
6/13/2003 | CV | New Issue: Durect $50 million convertibles yield 6.25%, up 25%
|
6/11/2003 | CV | Durect $50 million overnight convertibles talked to yield 5.75-6.25%, up 35-40%
|
6/11/2003 | CV | Market Commentary: Xerox emerges as a mandatory; Mirant in freefall; Tyco gains on unit sale talk; airlines fly high
|